LD50 >1 g/kg (rat) (W. Grell)
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to ? cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pegvisomant | The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Repaglinide. |
| Reserpine | Reserpine may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Progesterone | Progesterone may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Chlorpromazine | Chlorpromazine may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Cimetidine | Cimetidine may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Bosentan | Bosentan may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Tamoxifen | Tamoxifen may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Ethinylestradiol | Ethinylestradiol may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Glyburide | Glyburide may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Ursodeoxycholic acid | Ursodeoxycholic acid may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Cholic Acid | Cholic Acid may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Fusidic acid | Fusidic acid may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Simeprevir | Simeprevir may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Lenvatinib | Lenvatinib may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Letermovir | The metabolism of Repaglinide can be decreased when combined with Letermovir. |
| Valinomycin | Valinomycin may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Quinidine | Quinidine may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Olmesartan | Olmesartan may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Pralsetinib | Pralsetinib may decrease the excretion rate of Repaglinide which could result in a higher serum level. |
| Cyclosporine | The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine. |
| Erythromycin | The serum concentration of Repaglinide can be increased when it is combined with Erythromycin. |
| Sirolimus | The serum concentration of Repaglinide can be increased when it is combined with Sirolimus. |
| Dirithromycin | The serum concentration of Repaglinide can be increased when it is combined with Dirithromycin. |
| Telithromycin | The serum concentration of Repaglinide can be increased when it is combined with Telithromycin. |
| Candicidin | The serum concentration of Repaglinide can be increased when it is combined with Candicidin. |
| Clarithromycin | The serum concentration of Repaglinide can be increased when it is combined with Clarithromycin. |
| Josamycin | The serum concentration of Repaglinide can be increased when it is combined with Josamycin. |
| Everolimus | The serum concentration of Repaglinide can be increased when it is combined with Everolimus. |
| Epothilone D | The serum concentration of Repaglinide can be increased when it is combined with Epothilone D. |
| Patupilone | The serum concentration of Repaglinide can be increased when it is combined with Patupilone. |
| 6-Deoxyerythronolide B | The serum concentration of Repaglinide can be increased when it is combined with 6-Deoxyerythronolide B. |
| Ixabepilone | The serum concentration of Repaglinide can be increased when it is combined with Ixabepilone. |
| KOS-1584 | The serum concentration of Repaglinide can be increased when it is combined with KOS-1584. |
| Ridaforolimus | The serum concentration of Repaglinide can be increased when it is combined with Ridaforolimus. |
| Temsirolimus | The serum concentration of Repaglinide can be increased when it is combined with Temsirolimus. |
| AVE9633 | The serum concentration of Repaglinide can be increased when it is combined with AVE9633. |
| Coltuximab ravtansine | The serum concentration of Repaglinide can be increased when it is combined with Coltuximab ravtansine. |
| Cethromycin | The serum concentration of Repaglinide can be increased when it is combined with Cethromycin. |
| Mitemcinal | The serum concentration of Repaglinide can be increased when it is combined with Mitemcinal. |
| Brefeldin A | The serum concentration of Repaglinide can be increased when it is combined with Brefeldin A. |
| Solithromycin | The serum concentration of Repaglinide can be increased when it is combined with Solithromycin. |
| Kitasamycin | The serum concentration of Repaglinide can be increased when it is combined with Kitasamycin. |
| Carbomycin | The serum concentration of Repaglinide can be increased when it is combined with Carbomycin. |
| Doramectin | The serum concentration of Repaglinide can be increased when it is combined with Doramectin. |
| Eprinomectin | The serum concentration of Repaglinide can be increased when it is combined with Eprinomectin. |
| Oleandomycin | The serum concentration of Repaglinide can be increased when it is combined with Oleandomycin. |
| Selamectin | The serum concentration of Repaglinide can be increased when it is combined with Selamectin. |
| Tildipirosin | The serum concentration of Repaglinide can be increased when it is combined with Tildipirosin. |
| Tilmicosin | The serum concentration of Repaglinide can be increased when it is combined with Tilmicosin. |
| Tylosin | The serum concentration of Repaglinide can be increased when it is combined with Tylosin. |
| Tylvalosin | The serum concentration of Repaglinide can be increased when it is combined with Tylvalosin. |
| Bryostatin 1 | The serum concentration of Repaglinide can be increased when it is combined with Bryostatin 1. |
| Lorvotuzumab mertansine | The serum concentration of Repaglinide can be increased when it is combined with Lorvotuzumab mertansine. |
| Epofolate | The serum concentration of Repaglinide can be increased when it is combined with Epofolate. |
| Sagopilone | The serum concentration of Repaglinide can be increased when it is combined with Sagopilone. |
| Troleandomycin | The serum concentration of Repaglinide can be increased when it is combined with Troleandomycin. |
| Miocamycin | The serum concentration of Repaglinide can be increased when it is combined with Miocamycin. |
| Flurithromycin | The serum concentration of Repaglinide can be increased when it is combined with Flurithromycin. |
| Rokitamycin | The serum concentration of Repaglinide can be increased when it is combined with Rokitamycin. |
| Midecamycin | The serum concentration of Repaglinide can be increased when it is combined with Midecamycin. |
| Clindamycin | The serum concentration of Repaglinide can be increased when it is combined with Clindamycin. |
| Mepartricin | The serum concentration of Repaglinide can be increased when it is combined with Mepartricin. |
| Mifepristone | The serum concentration of Repaglinide can be increased when it is combined with Mifepristone. |
| Trimethoprim | The serum concentration of Repaglinide can be increased when it is combined with Trimethoprim. |
| Deferasirox | The serum concentration of Repaglinide can be increased when it is combined with Deferasirox. |
| Leflunomide | The serum concentration of Repaglinide can be increased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Repaglinide can be increased when it is combined with Teriflunomide. |
| Rifampin | The serum concentration of Repaglinide can be decreased when it is combined with Rifampicin. |
| Lipoic acid | The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Repaglinide. |
| Moxifloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Moxifloxacin. |
| Grepafloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Grepafloxacin. |
| Enoxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Enoxacin. |
| Pefloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Pefloxacin. |
| Ciprofloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Ciprofloxacin. |
| Trovafloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Trovafloxacin. |
| Nalidixic acid | The therapeutic efficacy of Repaglinide can be increased when used in combination with Nalidixic acid. |
| Rosoxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Rosoxacin. |
| Cinoxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Cinoxacin. |
| Lomefloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Lomefloxacin. |
| Gatifloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Gatifloxacin. |
| Norfloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Norfloxacin. |
| Levofloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Levofloxacin. |
| Gemifloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Gemifloxacin. |
| Ofloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Ofloxacin. |
| Sparfloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Sparfloxacin. |
| Temafloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Temafloxacin. |
| Fleroxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Fleroxacin. |
| Technetium Tc-99m ciprofloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Technetium Tc-99m ciprofloxacin. |
| Garenoxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Garenoxacin. |
| Nemonoxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Nemonoxacin. |
| Flumequine | The therapeutic efficacy of Repaglinide can be increased when used in combination with Flumequine. |
| Enrofloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Enrofloxacin. |
| Orbifloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Orbifloxacin. |
| Sarafloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Sarafloxacin. |
| Difloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Difloxacin. |
| Pazufloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Pazufloxacin. |
| Prulifloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Prulifloxacin. |
| Delafloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Delafloxacin. |
| Sitafloxacin | The therapeutic efficacy of Repaglinide can be increased when used in combination with Sitafloxacin. |
| Oxolinic acid | The therapeutic efficacy of Repaglinide can be increased when used in combination with Oxolinic acid. |